SelectQuote (SLQT)
NYSE:SLQT
Want to see SLQT full AI Analyst Report?
SLQT Stock Chart & Stats
$0.78
$0.12(2.90%)
At close: 4:00 PM EST
$0.78
$0.12(2.90%)
Day’s Range― - ―
52-Week Range$0.56 - $3.43
Previous CloseN/A
Volume368.25K
Average Volume (3M)1.09M
Market Cap
$132.50M
Enterprise Value$570.55M
Total Cash (Recent Filing)$22.20M
Total Debt (Recent Filing)$457.83M
Price to Earnings (P/E)0.9
Beta1.43
Next Earnings
May 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding176,289,660
10 Day Avg. Volume850,257
30 Day Avg. Volume1,094,945
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.73
Price to Sales (P/S)0.27
P/FCF Ratio-30.25
Enterprise Value/Market Cap4.31
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda3.50
Forecast
1Y Price Target
$4.00Price Target Upside412.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$1.66B
Bulls Say, Bears Say
Bulls Say
De-risked Balance SheetLeverage has fallen materially to ~0.14x debt-to-equity and equity is sizable versus assets, which meaningfully reduces refinancing and solvency risk. This durable improvement expands capital flexibility for AEP seasonality, strategic investments and cushions regulatory or partner shocks.
High Senior Margins And Strong Agent MetricsThe senior segment delivers structurally high margins (near‑record 39%) and >90% agent retention with rising productivity, creating a durable distribution advantage in Medicare markets. High productivity and retention lower acquisition cost and support consistent policy flow and renewal economics.
SelectRx Growth With Measurable Clinical ImpactRapid SelectRx revenue and membership growth plus demonstrated clinical outcomes (fewer hospital days) strengthen a recurring, value‑based services franchise. That diversification supports stable revenue streams, payer partnerships, and potential margin uplift from pharmacy services over time.
Bears Say
Inconsistent Cash GenerationCash conversion has been volatile with small absolute TTM OCF/FCF and prior-year negative periods. That inconsistency constrains reinvestment in marketing or agent incentives, increases reliance on debt or facilities for seasonality, and limits cushion against recurring industry shocks.
Thin, Recovery-dependent MarginsProfitability has recovered but remains modest and well below historical peaks. With narrow margins, SelectQuote is exposed to modest revenue or commission pressure from carriers, reimbursement or marketing shifts, making durable margin expansion uncertain without sustained execution.
Industry And Partner Headwinds Reduce VisibilityMaterial one‑time headwinds from PBM reimbursement adjustments and a major carrier marketing pullback signal structural volatility in partner economics. Such recurring carrier/PBM decisions can materially swing enrollments and commissions, undermining multi‑period revenue and EBITDA predictability.
SelectQuote News
SLQT FAQ
What was SelectQuote’s price range in the past 12 months?
SelectQuote lowest stock price was $0.56 and its highest was $3.43 in the past 12 months.
What is SelectQuote’s market cap?
SelectQuote’s market cap is $132.50M.
When is SelectQuote’s upcoming earnings report date?
SelectQuote’s upcoming earnings report date is May 05, 2026 which is in 13 days.
How were SelectQuote’s earnings last quarter?
SelectQuote released its earnings results on Feb 05, 2026. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.218 by $0.042.
Is SelectQuote overvalued?
According to Wall Street analysts SelectQuote’s price is currently Undervalued.
Does SelectQuote pay dividends?
SelectQuote does not currently pay dividends.
What is SelectQuote’s EPS estimate?
SelectQuote’s EPS estimate is >-0.01.
How many shares outstanding does SelectQuote have?
SelectQuote has 176,289,660 shares outstanding.
What happened to SelectQuote’s price movement after its last earnings report?
SelectQuote reported an EPS of $0.26 in its last earnings report, beating expectations of $0.218. Following the earnings report the stock price went down -28.966%.
Which hedge fund is a major shareholder of SelectQuote?
Currently, no hedge funds are holding shares in SLQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SelectQuote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (412.82% Upside)
$4.00 (412.82% Upside)
Blogger Sentiment
Bullish
SLQT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 63.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $104.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.01%
12-Months-Change
Fundamentals
Return on Equity
13.52%
Trailing 12-Months
Asset Growth
5.71%
Trailing 12-Months
Company Description
SelectQuote
SelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance policies to consumers from various insurance carriers in the United States. The company operates through three segments: Senior; Life; and Auto & Home. It distributes senior health policies, such as medicare advantage, medicare supplement, medicare part D, and other ancillary senior health insurance related policies, including prescription drugs, dental, vision, and hearing plans; term life policies; and non-commercial auto and home property, and casualty policies. The company was incorporated in 1999 and is headquartered in Overland Park, Kansas.
SLQT Company Deck
SLQT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong operational execution: double‑digit consolidated revenue growth, near‑record senior margins (39%), rapid SelectRx revenue growth (26% YoY) and measurable clinical outcomes (20% fewer hospital days). Management secured a multiyear PBM agreement and a $415M credit facility that materially improves visibility and capital flexibility. However, the quarter and fiscal 2026 guidance were meaningfully impacted by two discrete headwinds (~$20M PBM reimbursement adjustment and ~$20M from a national carrier marketing cut), prompting a revised adjusted EBITDA range of $90–$100M and signaling near‑term uncertainty from industry disruption and preliminary CMS rate guidance. Overall the operational and cash flow improvements and strategic balance sheet actions outweigh the near‑term, largely one‑time headwinds, leaving management optimistic about long‑term profitability and cash generation.View all SLQT earnings summariesSLQT Stock 12 Month Forecast
Average Price Target
$4.00
▲(412.82% Upside)
Technical Analysis
Ownership Overview
29.71% Insiders
7.57% Mutual Funds
0.06% Other Institutional Investors
53.89% Public Companies and
Individual Investors